cycloserine has been researched along with Anankastic Personality in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (25.00) | 29.6817 |
| 2010's | 22 (68.75) | 24.3611 |
| 2020's | 2 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Cadman, J; Farrell, LJ; Garbharran, V; Geller, D; Hudson, JL; Lavell, C; Mathieu, S; McConnell, H; McDermott, B; McKenzie, M; Ollendick, TH; Rapee, RM; Storch, EA; Tiralongo, E; Ware, RS; Waters, AM; Zimmer-Gembeck, MJ | 1 |
| Abramowitz, JS; Børtveit, T; Craske, MG; Franklin, ME; Hagen, K; Hansen, B; Haseth, S; Himle, JA; Hystad, S; Kristensen, UB; Kvale, G; Launes, G; Lund, A; Öst, LG; Solem, S | 1 |
| Berman, N; Geller, D; Porth, R; Small, BJ; Storch, EA; Wilhelm, S | 1 |
| Grassi, G; Pallanti, S | 1 |
| Geller, DA; McGuire, JF; Murphy, TK; Orr, SP; Porth, R; Small, BJ; Storch, EA; Trainor, K; Wilhelm, S | 1 |
| Geller, DA; McGuire, JF; Murphy, TK; Schneider, SC; Small, BJ; Storch, EA; Wilhelm, S | 1 |
| Boschen, MJ; Collings, N; Farrell, LJ; Hattingh, L; McConnell, H; Milliner, EL; Ollendick, TH; Shelton, D; Storch, EA; Testa, C; Waters, AM; Zimmer-Gembeck, M | 1 |
| Heyman, I; Isomura, K; Krebs, G; Mataix-Cols, D; Monzani, B; Murphy, C; Turner, C | 1 |
| Dodds, A; Rapp, A; Rynn, M; Walkup, JT | 1 |
| Lewin, AB; McGuire, JF; Storch, EA | 1 |
| Du, Y; Han, J; Liu, G; Wang, X; Xia, J | 1 |
| Andersson, E; Andersson, G; Cervenka, S; Enander, J; Hedman, E; Isung, J; Kaldo, V; Lindefors, N; Ljótsson, B; Mataix-Cols, D; Radu Djurfeldt, D; Rück, C; Svanborg, C | 1 |
| Heyman, I; Isomura, K; Krebs, G; Mataix-Cols, D; Monzani, B; Olatunji, BO; Rosenfield, D; Turner, C | 1 |
| Fang, A; Wilhelm, S | 1 |
| McCracken, JT; McGuire, JF; Piacentini, J; Storch, EA; Wu, MS | 1 |
| Geller, DA; Henin, A; Lewin, AB; McGuire, J; Micco, J; Murphy, TK; Mutch, PJ; Small, BJ; Sprich, S; Storch, EA; Wilhelm, S | 1 |
| Altemus, M; Anderson, P; Andersson, E; Cukor, J; Davis, M; de Kleine, RA; Difede, J; Dunlop, BW; Farrell, LJ; Fernández de la Cruz, L; Finck, C; Frumento, P; Geffken, GR; Geller, D; Gerardi, M; Golfels, F; Goodman, WK; Guastella, AJ; Gutner, C; Hendriks, GJ; Heyman, I; Hofmann, SG; Jovanovic, T; Kushner, MG; Lee, FS; Lenze, EJ; Levinson, CA; Lewin, AB; Mataix-Cols, D; McConnell, H; McNamara, JP; Monzani, B; Murphy, TK; Norrholm, S; Otto, MW; Pérez-Vigil, A; Plag, J; Pollack, MH; Ressler, KJ; Rodebaugh, TL; Rosenfield, D; Rothbaum, BO; Rück, C; Scheeringa, MS; Siewert-Siegmund, A; Smits, JAJ; Storch, EA; Ströhle, A; Tart, CD; Thuras, P; Tolin, DF; van Minnen, A; Waters, AM; Weems, CF; Wilhelm, S; Wyka, K | 1 |
| Michopoulos, V | 1 |
| Bittner, N; Buhlmann, U; Bürkner, PC; Holling, H | 1 |
| Hammonds, MD; Shim, SS; Vrabel, MM | 1 |
| McKay, D; Tryon, WW | 1 |
| Mariaskin, A; Murphy, TK; Storch, EA | 1 |
| Albelda, N; Bar-On, N; Joel, D | 1 |
| Buhlmann, U; Chasson, GS; Rao, SR; Reese, HE; Rowley, T; Tolin, DF; Welsh, KS; Wilhelm, S | 1 |
| Bengtson, M; Geffken, GR; Geller, DA; Goodman, WK; Henin, A; Lewin, AB; Micco, JA; Murphy, TK; Sprich, S; Storch, EA; Wilhelm, S | 1 |
| Choi, DC; Gerardi, M; Ressler, KJ; Rothbaum, BO | 1 |
| Herpertz-Dahlmann, B; Simons, M; Vloet, TD | 1 |
| Bengtson, M; Fernandez, M; Geffken, GR; Goodman, WK; Hirsh, A; Jacob, ML; Larson, M; Lewis, MH; Merlo, LJ; Murphy, TK; Storch, EA; Yang, MC | 1 |
| Adson, D; Donahue, C; Foa, EB; Kim, SW; Kotlyar, M; Kushner, MG; McCabe, J; Peterson, J; Thuras, P | 1 |
| Hofmann, SG | 1 |
| Buhlmann, U; Cannistraro, P; Jenike, MA; Meunier, SA; Pearlson, GD; Rauch, SL; Reese, HE; Tolin, DF; Wilhelm, S | 1 |
| Rothbaum, BO | 1 |
13 review(s) available for cycloserine and Anankastic Personality
| Article | Year |
|---|---|
Current and up-and-coming pharmacotherapy for obsessive-compulsive disorder in adults.
Topics: Adult; Anticonvulsants; Cycloserine; Excitatory Amino Acid Agents; Humans; Obsessive-Compulsive Disorder; Oligopeptides; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate | 2018 |
Treatment of pediatric anxiety disorders.
Topics: Adolescent; Anticonvulsants; Anxiety Disorders; Anxiety, Separation; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Cycloserine; Humans; Obsessive-Compulsive Disorder; Phobic Disorders; Riluzole; Stress Disorders, Post-Traumatic | 2013 |
Enhancing exposure therapy for anxiety disorders, obsessive-compulsive disorder and post-traumatic stress disorder.
Topics: Animals; Anxiety Disorders; Behavior Therapy; Cycloserine; Humans; Obsessive-Compulsive Disorder; Randomized Controlled Trials as Topic; Stress Disorders, Post-Traumatic; Yohimbine | 2014 |
D-cycloserine augmentation in behavioral therapy for obsessive-compulsive disorder: a meta-analysis.
Topics: Behavior Therapy; Combined Modality Therapy; Cycloserine; Humans; Obsessive-Compulsive Disorder; Treatment Outcome | 2015 |
A Meta-Analysis of D-Cycloserine in Exposure-Based Treatment: Moderators of Treatment Efficacy, Response, and Diagnostic Remission.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Child; Combined Modality Therapy; Cycloserine; Female; Humans; Implosive Therapy; Male; Middle Aged; Obsessive-Compulsive Disorder; Psychiatric Status Rating Scales; Psychometrics; Randomized Controlled Trials as Topic; Stress Disorders, Post-Traumatic; Treatment Outcome; Young Adult | 2017 |
D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data.
Topics: Antidepressive Agents; Anxiety Disorders; Combined Modality Therapy; Cycloserine; Drug Synergism; Excitatory Amino Acid Agonists; Humans; Implosive Therapy; N-Methylaspartate; Obsessive-Compulsive Disorder; Outcome Assessment, Health Care; Stress Disorders, Post-Traumatic | 2017 |
D-cycloserine augmentation of behavior therapy for anxiety and obsessive-compulsive disorders: A meta-analysis.
Topics: Anxiety Disorders; Bayes Theorem; Cycloserine; Humans; Implosive Therapy; Obsessive-Compulsive Disorder | 2017 |
Memory modification as an outcome variable in anxiety disorder treatment.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Cognitive Behavioral Therapy; Combined Modality Therapy; Cycloserine; Humans; Learning; Memory Disorders; Obsessive-Compulsive Disorder; Stress Disorders, Post-Traumatic; Treatment Outcome | 2009 |
Psychotherapy for obsessive-compulsive disorder.
Topics: Adult; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Controlled Clinical Trials as Topic; Cycloserine; Desensitization, Psychologic; Empirical Research; Humans; Obsessive-Compulsive Disorder; Outcome Assessment, Health Care; Psychotherapy, Group; Serotonin Agents; Therapy, Computer-Assisted; Treatment Outcome | 2009 |
Pharmacological enhancement of behavioral therapy: focus on posttraumatic stress disorder.
Topics: Animals; Anxiety Disorders; Cognitive Behavioral Therapy; Combined Modality Therapy; Cycloserine; Desensitization, Psychologic; Extinction, Psychological; Eye Movement Desensitization Reprocessing; Humans; Hypnosis; Implosive Therapy; Obsessive-Compulsive Disorder; Panic Disorder; Phobic Disorders; Receptors, N-Methyl-D-Aspartate; Stress Disorders, Post-Traumatic; Treatment Outcome | 2010 |
[Psychotherapeutic and pharmacological treatment of pediatric obsessive-compulsive disorder].
Topics: Adolescent; Antipsychotic Agents; Child; Clomipramine; Cognitive Behavioral Therapy; Combined Modality Therapy; Cycloserine; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Humans; Implosive Therapy; Obsessive-Compulsive Disorder; Riluzole; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2012 |
Enhancing exposure-based therapy from a translational research perspective.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Combined Modality Therapy; Cycloserine; Desensitization, Psychologic; Extinction, Psychological; Humans; Obsessive-Compulsive Disorder; Panic Disorder; Phobic Disorders | 2007 |
Critical parameters for D-cycloserine enhancement of cognitive-behaviorial therapy for obsessive-compulsive disorder.
Topics: Animals; Cognitive Behavioral Therapy; Combined Modality Therapy; Cycloserine; Glutamates; Humans; Implosive Therapy; Obsessive-Compulsive Disorder; Receptors, N-Methyl-D-Aspartate; Synapses; Synaptic Transmission; Treatment Outcome | 2008 |
15 trial(s) available for cycloserine and Anankastic Personality
| Article | Year |
|---|---|
Efficacy of D-cycloserine augmented brief intensive cognitive-behavioural therapy for paediatric obsessive-compulsive disorder: A randomised clinical trial.
Topics: Adolescent; Antidepressive Agents; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Cycloserine; Humans; Obsessive-Compulsive Disorder; Treatment Outcome | 2022 |
Effect of D-Cycloserine on the Effect of Concentrated Exposure and Response Prevention in Difficult-to-Treat Obsessive-Compulsive Disorder: A Randomized Clinical Trial.
Topics: Adult; Anti-Anxiety Agents; Cycloserine; Female; Humans; Implosive Therapy; Male; Middle Aged; Obsessive-Compulsive Disorder; Patient Satisfaction; Treatment Outcome; Young Adult | 2020 |
D-Cycloserine augmentation of cognitive behavior therapy for pediatric OCD: Predictors and moderators of outcome.
Topics: Adolescent; Antimetabolites; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Cycloserine; Female; Humans; Male; Obsessive-Compulsive Disorder; Problem Solving; Treatment Outcome | 2018 |
Fear extinction learning as a predictor of response to cognitive behavioral therapy for pediatric obsessive compulsive disorder.
Topics: Adolescent; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Conditioning, Classical; Cycloserine; Extinction, Psychological; Fear; Female; Humans; Male; Obsessive-Compulsive Disorder; Phobic Disorders; Treatment Outcome | 2019 |
Sudden gains in cognitive behavioral therapy among children and adolescents with obsessive compulsive disorder.
Topics: Adolescent; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Cycloserine; Double-Blind Method; Female; Humans; Male; Neurotransmitter Agents; Obsessive-Compulsive Disorder; Outcome Assessment, Health Care | 2019 |
Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and preliminary results of a randomized pilot trial of D-cycloserine-augmented behavior therapy.
Topics: Adolescent; Antimetabolites; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Cycloserine; Double-Blind Method; Extinction, Psychological; Feasibility Studies; Female; Humans; Implosive Therapy; Male; Obsessive-Compulsive Disorder; Pilot Projects; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 2013 |
Cognitive-behavioural therapy with post-session D-cycloserine augmentation for paediatric obsessive-compulsive disorder: pilot randomised controlled trial.
Topics: Animals; Cognitive Behavioral Therapy; Combined Modality Therapy; Cycloserine; Double-Blind Method; Extinction, Psychological; Fear; Humans; Intention to Treat Analysis; Obsessive-Compulsive Disorder; Pilot Projects; Placebos; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 2014 |
D-Cycloserine vs Placebo as Adjunct to Cognitive Behavioral Therapy for Obsessive-Compulsive Disorder and Interaction With Antidepressants: A Randomized Clinical Trial.
Topics: Adult; Aged; Antidepressive Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; Cycloserine; Double-Blind Method; Female; Humans; Internet; Male; Middle Aged; Obsessive-Compulsive Disorder; Receptors, N-Methyl-D-Aspartate; Therapy, Computer-Assisted; Treatment Outcome; Young Adult | 2015 |
EFFECTS OF HOMEWORK COMPLIANCE ON COGNITIVE-BEHAVIORAL THERAPY WITH D-CYCLOSERINE AUGMENTATION FOR CHILDREN WITH OBSESSIVE COMPULSIVE DISORDER.
Topics: Adolescent; Adolescent Behavior; Antimetabolites; Child; Cognitive Behavioral Therapy; Cycloserine; Female; Humans; Male; Obsessive-Compulsive Disorder; Patient Compliance | 2015 |
Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Amygdala; Body Weight; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Cycloserine; Dose-Response Relationship, Drug; Female; Humans; Male; Obsessive-Compulsive Disorder; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 2016 |
Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine.
Topics: Adult; Behavior Therapy; Combined Modality Therapy; Cycloserine; Female; Humans; Interview, Psychological; Male; Middle Aged; Obsessive-Compulsive Disorder; Psychiatric Status Rating Scales; Psychotropic Drugs; Self-Assessment; Time Factors; Treatment Outcome; Young Adult | 2010 |
A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder.
Topics: Adolescent; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Cycloserine; Double-Blind Method; Female; Humans; Linear Models; Male; Obsessive-Compulsive Disorder; Psychiatric Status Rating Scales; Treatment Outcome | 2010 |
D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Behavior Therapy; Combined Modality Therapy; Cycloserine; Double-Blind Method; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Placebos; Psychiatric Status Rating Scales; Receptors, N-Methyl-D-Aspartate | 2007 |
D-cycloserine augmented exposure therapy for obsessive-compulsive disorder.
Topics: Behavior Therapy; Combined Modality Therapy; Cycloserine; Double-Blind Method; Excitatory Amino Acid Agonists; Extinction, Psychological; Humans; Obsessive-Compulsive Disorder; Patient Compliance; Patient Dropouts; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 2007 |
Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder.
Topics: Adult; Animals; Behavior Therapy; Combined Modality Therapy; Cycloserine; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Follow-Up Studies; Humans; Implosive Therapy; Obsessive-Compulsive Disorder; Placebos; Psychiatric Status Rating Scales; Rats; Receptors, N-Methyl-D-Aspartate; Secondary Prevention; Severity of Illness Index; Treatment Outcome | 2008 |
4 other study(ies) available for cycloserine and Anankastic Personality
| Article | Year |
|---|---|
Antidepressant use with d-Cycloserine may block fear extinction.
Topics: Antidepressive Agents; Cognitive Behavioral Therapy; Cycloserine; Female; Humans; Male; Obsessive-Compulsive Disorder | 2016 |
Enhancing cognitive behavioral therapy: Is the finish line in sight?
Topics: Anxiety; Anxiety Disorders; Cognitive Behavioral Therapy; Combined Modality Therapy; Cycloserine; Humans; Obsessive-Compulsive Disorder; Stress Disorders, Post-Traumatic | 2017 |
D-cycloserine augmentation for behavioral therapy.
Topics: Antimetabolites; Cognitive Behavioral Therapy; Combined Modality Therapy; Cycloserine; Glycine; Humans; Obsessive-Compulsive Disorder | 2008 |
The role of NMDA receptors in the signal attenuation rat model of obsessive-compulsive disorder.
Topics: Animals; Cycloserine; Disease Models, Animal; Dizocilpine Maleate; Dose-Response Relationship, Drug; Extinction, Psychological; Male; Obsessive-Compulsive Disorder; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Signal Transduction | 2010 |